Abstract: |
Carbohydrate cell surface antigens have proved to be unexpectedly potent targets for immune recognition and attack against cancers [1]. Of the many tumor-restricted monoclonal antibodies derived by immunization of mice with human tumor cells, most have been directed against carbohydrate antigens expressed at the cell surface as glycolipids or mucins [2-4]. Antibodies against cell surface antigens such as these are ideally suited for eradication of free tumor cells and micrometastases. In adjuvant immunization trials, the primary targets are individual tumor cells or early micrometastases which may persist for long periods after apparent resection of all residual tumor [5-7]. After surgery and completion of chemotherapy is the ideal time for immune intervention, and in particular for administration of cancer vaccines aimed at instructing the immune system to identify and kill these few remaining cancer cells. If antibodies of sufficient titer can be induced against tumor antigens to eliminate tumor cells from the blood and lymphatic systems, and to eradicate micrometastases (making establishment of new metastases no longer possible) this would dramatically change our approach to treating the cancer patient. Aggressive local therapies, including surgery, radiation therapy and intralesional treatments might result in long term control of even metastatic cancers. |